A venture arm of one of the largest non-profit health systems in the seeks to foster the commercialization of internal ideas as well as external innovation. To date, the firm has been focusing in Series A to B rounds but expect to look into more early-stage opportunities in the future. Initial size of investment can range from $500K – 1M. The firm invests off a balance sheet and has no dedicated fund. The firm is focused on partnering and investing in companies based in the USA.
The firm is interested in piloting and investing in technologies that strategically align with the interests of a large integrated delivery network. This includes both the organization’s existing priority areas, along trying to improve the health system’s strategic position in the future. Areas of interest include improving the ratings and member retention in our Medicaid and Medicare Advantage insurance plans, recruiting and retaining clinicians, process optimization, the coming consumerization of healthcare, back-office optimization, and more. The firm is primarily looking for digital health solutions, but will consider some 510k medical devices. The firm is not interested in therapeutics or diagnostics.
The firm has no specific company or management team requirements. The firm prefers to co-invest alongside syndicate partners.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Venture Arm of Non-Profit Health System Seeks Strategic Investments Mainly USA-Based Digital Health Companies, Will Consider 510K Devices
14 AprHot Investor Mandate: USA Investment Firm and Venture Builder Seeks Early-Stage Therapeutics Companies in North America, Europe, and Israel With Strong IP
14 AprAn investor and venture builder based in the USA invests in pre-clinical therapeutics companies, frequently taking a majority stake and playing an active role in the company’s development. The firm is open to all therapeutic types and indications, currently they have a particular interest in Infectious Disease technologies to partner and or invest with a current portfolio company. The firm will generally invest $1-5M, and will invest globally, with previous investments in North America, Europe and Israel.
The firm is interested only in therapeutics companies, but will consider all types of therapeutics in all indications. The firm invests from discovery to preclinical stage and will support companies development efforts.
The firm prefers to lead and take a majority stake in their portfolio companies, and then act as a venture builder. The firm is interested only in companies that have strong IP portfolios.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Selling, Cold Calling, and Follow-Up Are Not Dirty Words
12 AprBy Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
The coaching and mentoring universe is divided between those who think that selling, cold calling, and follow-ups are dirty words. They’re likely to proselytize that if you do not have a warm referral, you are wasting your time. The other camp (where I live) supports finding partners based on the fit of product and stage of development and reaching out until you book that meeting or are told, “No.” Life Science Nation created the RESI conference to be a vehicle to make this happen, based on fit – the other “warm referral.”
Opportunity abounds in the golden age of life science with new tools and technologies adding to the dynamic, but we’re also seeing startups fail faster, and therefore pivot, restart, and draw a straighter line to viable targets and products. I hear frequently that the magic combination is being smart and lucky, but somewhere in the middle of being smart and lucky is determination, commitment to hard, tedious work, and navigating the path to a new product. This is the case for founders taking their companies from regional to global and finding investors and licensing partners that are a fit.
RESI is a conference designed for these entrepreneurs to flourish. It’s frustrating to see partnering events with little vetted investors or licensing partners, but rather services providers wanting to charge for their partnering services. These other partnering events are more of a social gathering for reconnecting business acquaintances, which makes it a challenge in choosing the right event for you. None of this is inherently wrong, but the current need is for real vetted partners who are looking to fulfil investment mandates and product pipelines.
The early-stage marketplace is heating up with growing buy-side players seeking these startups. Join us for Digital RESI, June 7-9 and mark your calendar for the first in-person RESI since 2020 – RESI Boston, September 21-22.
AI & Longevity at RESI
7 AprBy Caitlin Dolegowski, Marketing Specialist, LSN
The Redefining Early Stage Investments (RESI) conference series proudly highlights active investors, early-stage founders, and industry leaders advancing drugs, devices, diagnostics, and digital health. RESI is unique in its focus on early-stage life science and healthcare, but in recent years, has gone even further to cut out space specifically for artificial intelligence (AI) and age-tech innovation. To do this, RESI conferences feature specialized content for startups and strategic partners in these industries through dedicated panels and pitch competitions.
Innovative advancements within these industries and a deep dive into insights around how to navigate the early-stage investment ecosystem specific to conversations happening in AI and Longevity arenas are a major addition and highlight at RESI. Panels provide discussions with investors, industry experts, entrepreneurs, and strategic partners answering questions about early-stage fundraising and age-tech and AI innovation.
View sample panel sessions from Digital RESI March:
LONGEVITY
Digital Health & Wellness
Silver-Tech Focusing on Preventative Care
According to the US Census Bureau, the 65+ population grew by 34% since 2010. These seniors are prioritizing preventative care and the market is responding with products and services focused on staying healthy, specifically those focused on daily exercise, diet, and other factors impacting independence and longevity. How can startups in this booming industry stand out to investors?
AI
Defining AI Investment
AI-Exclusive Investors Share Their Perspectives
Hear from leaders investing exclusively in AI products across drugs, devices, diagnostics, and digital health. Learn more about what AI-exclusive investors have to offer healthtech startups. Learn what entrepreneurs can gain from partnerships that understand their tech and how to take it to the next level.
The lens on age-tech and AI continues at our next conference, Digital RESI, June 7-9. The focus on these markets will include panel topics:
LONGEVITY
Tuesday, June 7 – 2PM EDT | The Neuroscience of Aging
Aging Impact on the Nervous System
Age-tech startups are addressing negative impacts of neurological aging, such as cognitive decline, dementia, and Alzheimer’s. The goal of many of these early-stage companies is to stimulate neurogenesis and enhance brain plasticity to combat these conditions.
Thursday, June 9 – 11 AM EDT – Age-Tech Care Management
Technology Improving the Lives of Older Adults
Older adults are looking to age-tech to provide freedom, medical access & adherence, safety, wellness and even companionship later in life. Age-tech allows seniors, and their caregivers make personalized choices about their own aging journeys. Hear from investors specializing in longevity innovation.
AI
Wednesday, June 8 – 11 AM EDT – AI vs. Life Science
Which Comes First in Early-Stage Investment?
How to prioritize tech-first vs. biology models? How can each model leverage their position in the industry and be successful in the early stage? How can startup founders balance the “bio” and “tech” and highlight their strengths to investors? What are some strategies to help fundraising executives target the right investors for their company and pivot their pitch to each?
Thursday, June 9 – 2 PM EDT – Team, Tech, & Traction in Early-Stage AI
Building Your Startup as a Triple Threat
Early-stage investors will take a chance on a team, tech, or traction. It’s rare to find all three in a company seeking Seed to Series B funding. This discussion will explore the value of each to help early-stage startups highlight their unique assets and improve their position in weaker areas.
Register by April 15 to save $300 with our Super Early Bird rates.
The Angel on Your Shoulder
7 AprBy Megan Rychwa, Investor Research Analyst, LSN
Anyone embroiled in early-stage fundraising understands the need for solid advice and warm introductions, especially when approaching angel investors and family offices – your own shoulder angel to guide your progress. These investor groups are popular at Redefining Early Stage Investments (RESI) conferences because they offer insights to founders on how to connect and engage with these types of investors.
When it comes to approaching family offices and angels, your network is everything. Faz Bashi of Life Science Angels said at RESI June 2021 “BYNBYNI – build your network before you need it.” As a life science start-up, getting to know the members within an angel group or family office, connecting via LinkedIn, going to events hosted by the angel group or family office and conferences like RESI, and building your network before even asking for money is going to set you apart from other startups. When you are known within the networks, the angels will talk to one another and can provide referrals and deal flow, giving you a warm call to the investor you want to meet with. Cold calls are not an efficient way to connect with investors in general, but especially not with angels and family offices. The gatekeepers may turn you down before you can even pitch your company.
Many angels and family offices have a vast network, and Charles Cameron of Hub Angels Investment Group told his panel at RESI September 2021 that if you cannot get a referral through the network, you are not connected and you are not the right person for the job. Since COVID, your network is even more critical, and you want to be well-connected before even thinking about raising money. Charles explained, “Use the network, get a referral in, do it early, early, and often. I love when people keep me updated before they need the money… Here is an update on the company and I have watched them over time, and you suddenly are building a relationship with that person of trust and insight.” Find a contact and get into the network of angels and family offices you are targeting, and keep people informed on your company’s technology and successes and do it before you need money, so you are already well-known and trusted.
Another key factor in approaching angels and family offices is preparedness. The investors within these groups do a lot of due diligence and research on your company, they ask you to do the same. When approaching an investor, going on their website can make you as an entrepreneur stand out; know their investment criteria, know their portfolio companies, and keep up-to-date with the latest news on the group. Nadav Shimoni of Arkin Holdings said at RESI June 2021 that he expects entrepreneurs to go through their website and portfolio and come to the table saying, “I know this is the type of technologies that get you excited because you’ve invested in it, I really like this blog post you’ve shared, and we are doing something similar.” This shows that they are diligent in the process and will be diligent as a company.
Some angel and family office groups, such as MidAtlantic Bio Angels, have office hours where, before asking for any money at all, a startup can come in with an idea or the preliminary stages of their company and pitch to investors for feedback and advice, so they are ready for the future when they are pitching for money. Doing this builds a relationship within the group early on and if that relationship continues throughout the preliminary stages of the company, that trust has been built and maintained which helps get to the investment stage much easier through connections and networking.
Building your network is the key to success with connecting with angels and family offices, and events like RESI make doing that easier than ever before. When you have built a solid network, that foundation gives your company a lot more credibility and trustworthiness to investors who invest out of their own pockets. Let these principles guide your outreach like a shoulder angel so you can be ready when the real ones come knocking.
Top 10 Challenges for Startups Raising Capital and Seeking Licensing Deals
7 AprBy Dennis Ford, Founder and CEO of Life Science Nation, Creator of the LSN Partnering Conference Series
Check out a recent list of the top challenges startups face when entering the early-stage fundraising arena. Each challenge is linked to an article tackling these and similar issues.
- Migrating from regional mindset to global partnering arena
- Understanding that deals take 9-18 months and identifying vehicles that can assist in partnering campaigns early
- Defining and understanding their competitive landscape
- Compiling a global target list (GTL) that is a fit for product and stage of development
- Understanding the cost of launching and executing a global partnering campaign ($60K-$90K)
- Developing branding and messaging that highlights unique company value that is clear, concise, and easy to understand
- Implementing a CRM to activate and organize global campaign, which includes ongoing curation of partner list, outreach initiatives, and tracks status and to-do list for all meetings
- Hitting the road with phone and email canvassing, as well as traveling to conferences to engage partners
- Learning the art of follow-up (99% of all startups fail here)
- Learning how to efficiently partner at a partnering conference
Life Science Nation is committed to facilitating well-fitting meetings between founders with innovative assets and the capital and channel partners who seek them. Join us for one of our free fundraising bootcamps to learn about the products and services we offer to the startup community in life science and healthcare.
Our Redefining Early Stage Investments (RESI) conference returns in a virtual format June 7-9. Register today and save $300 on super early bird rates by April 15!
Hot Investor Mandate: Healthcare-Focused Firm Seeks to Invest Up to $50M in High Potential Clinical, Later-Stage Opportunities Close to Commercialization
7 AprA healthcare-focused Venture Capital and Growth Equity firm currently manages ~$1 billion, providing $15-$50 million of equity capital per company over the life of the investment. With offices in USA and Europe, the firm is primarily looking for companies throughout North America and Europe.
The firm is currently interested in companies in areas of medical technology, biopharmaceuticals, diagnostics, medical devices, life sciences tools, digital health, and veterinary medicine. Significant emphasis is placed on the clinical utility and health economics of potential investments. The firm focuses on later-stage opportunities that are already commercialized or are close to commercialization. The firm is open in terms of indications.
The firm looks for management teams that are very willing to work alongside them, and the firm generally looks to take a board seat. The firm is open to investing in both public and privately held companies, is open to a variety of deal structures, and can consider equity investments or buy-out opportunities.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.












